Dr. Reddys Laboratories Ltd.

Dr Reddy’s Laboratories (DRL) has entered into an agreement with Hetero, under which DRL has been licensed to distribute and market Sofosbuvir 400 mg tablets, indicated in the treatment of Chronic Hepatitis C, under the brand name Resof, in India.

With the diagnosis rates for Hepatitis C in India being abysmally low, DRL will make a significant difference in the diagnosis and treatment of this disease.

Resof is a breakthrough medicine and will simplify the traditional and complicated treatment options available nowadays, allowing patients suffering from Chronic Hepatitis C access to a far more affordable and effective treatment regimen, as compared to existing ones.

Dr Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.